AHK-Cu Dosage Chart: Topical Serum Prep

AHK-Cu is a copper-binding tripeptide used topically rather than by injection. The research powder — alanine-histidine-lysine complexed with copper(II) — is reconstituted into a serum and applied to the scalp or skin, often alongside microneedling. This makes "dosing" a question of concentration and application frequency, not injected milligrams.

The honest framing matters here: AHK-Cu has no established human dosing protocol. The most-cited study (Pyo et al. 2007, PMID 17703734) tested AHK-Cu on isolated human hair follicles and dermal papilla cells in culture at picomolar-to-nanomolar concentrations — not as a topical product on people. So the numbers below come from self-reported community formulations and from the lesser sibling relationship to GHK-Cu, not from clinical dose-finding. They're reported as what community sources describe, not as instructions.

Research-context information only. AHK-Cu is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Quick Reference: Protocol

Community-reported AHK-Cu use centers on a topical serum applied to the scalp (for hair interest) or skin (for the copper-peptide skin properties extrapolated from GHK-Cu). The recurring elements in self-reported formulations:

• Format: lyophilized research powder reconstituted into an aqueous serum, not an injectable.
• Concentration: community-reported topical serums commonly fall in the ~1-2 mg/mL range (roughly 0.1-0.2%), described for daily scalp application.
• Frequency: once or twice daily application is the most common self-reported cadence.
• Penetration aid: some community protocols pair application with microneedling, drawn from microneedling's documented role in androgenetic-alopecia studies (Dhurat et al. 2013, PMID 23960389) rather than from AHK-Cu trials specifically.

These are descriptive of what community sources document, not a recommended regimen. No controlled human trial has validated a topical AHK-Cu concentration or schedule.

Routes of Administration

AHK-Cu's route in community use is topical only. The two recommended vendors we track — Ion Peptide and Glacier Aminos — sell it as research powder, and community practice is to dissolve that powder into a serum for scalp or skin application. There is no community injection protocol for AHK-Cu, and this guide does not describe one.

Topical copper-peptide delivery has a documented limitation worth stating plainly: the skin barrier limits how much of a peptide reaches the dermis. This is why community protocols sometimes combine AHK-Cu serum with microneedling. The microneedling evidence base is for delivering established hair compounds — a randomized pilot of microneedling plus minoxidil (PMID 23960389) reported greater hair-count change than minoxidil alone, and a 2025 study of copper-peptide microneedling for androgenetic alopecia (PMID 40225275) reported measurable regrowth — neither study tested AHK-Cu as a standalone topical. The penetration rationale is borrowed, not AHK-Cu-specific.

Reconstitution Quick Reference

Because AHK-Cu is prepared as a topical serum, "reconstitution" here means dissolving the dry powder into a carrier to reach a target concentration, not drawing units for injection. The table below illustrates how community-reported concentrations map to a finished serum. These are illustrative figures derived from community formulation reports, not a clinical protocol.

A finished copper-peptide serum is light- and oxidation-sensitive and is generally kept refrigerated and used within a short window; community sources typically mix small batches rather than large ones. The carrier and any preservatives are part of the formulation question and vary across self-reported recipes.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

It's worth being explicit about provenance, because AHK-Cu attracts confident-sounding dose claims that the evidence doesn't support. The picomolar-to-nanomolar concentrations in the Pyo 2007 study (PMID 17703734) describe what was effective on cells in a dish; they are not a topical formulation percentage and cannot be read across to one. The ~1-2 mg/mL serum figures circulating in community sources are DIY formulation conventions, often borrowed from how GHK-Cu cosmetic serums are mixed, rather than results of any AHK-Cu human study.

In short: the cell-culture data establishes biological plausibility for hair-follicle effects; the topical concentrations are community formulation practice. Both are reported here for completeness, with the gap between them stated rather than glossed over. Anyone treating a serum percentage as a validated dose is reading more certainty into the literature than exists.

Stacking Protocols

Community sources sometimes describe layering AHK-Cu with GHK-Cu in a copper-peptide skin or scalp routine, on the rationale that the two copper tripeptides have overlapping but distinct profiles — GHK-Cu carrying the larger collagen and wound-healing literature (Pickart & Margolina 2018, PMID 29986520) and AHK-Cu the narrower hair-follicle signal. This is a community formulation pattern, not a tested combination.

For hair specifically, community routines more often pair a copper-peptide serum with microneedling and with established topicals rather than stacking two peptides. As above, the microneedling rationale rests on studies of other compounds (PMID 23960389, PMID 40225275), not on AHK-Cu data. No stack here is backed by a controlled trial; they're documented as what community sources describe.

Side Effects & Safety

Topical copper peptides are generally well tolerated in cosmetic use, with the main documented concerns being local: irritation, redness, or, less commonly, allergic contact dermatitis. Copper itself is a comparatively weak skin sensitizer — a 2014 review (PMID 25098945) reported positive copper patch-test reactions in roughly 3.8% of tested subjects — so contact allergy is possible but uncommon. Microneedling, where used as a penetration aid, adds its own local risks (transient redness, pinpoint bleeding) independent of the peptide.

Formal safety data specific to topical AHK-Cu is limited, and theoretical concerns such as copper accumulation with heavy long-term use have not been characterized in human studies. The fuller tolerability picture is covered in the AHK-Cu side effects article.